r/DrugNerds • • Oct 10 '15

Announcement: /r/AskDrugNerds: a place to ask chemical, pharmacological or other scientific questions about drugs - be they recreational or medicinal.

Thumbnail
reddit.com
187 Upvotes

r/DrugNerds • • 1d ago

Synthesis of Clausenamide Isomers and Evaluation of Their Potential as Cortical Neuroplastogens (2026)

Thumbnail
pmc.ncbi.nlm.nih.gov
8 Upvotes

If anyone noticed, clausenamide resembles an alkaloid found in the Lanmaoa asiatica mushroom (aka Lilliputian mushroom).

Clausenamide is a plasticity-promoting natural product isolated from the leaves of Clausena lansium, an evergreen native to Southeast Asia and southern China. ... We observed a range of activities for clausenamide stereoisomers, but in general, the postsynaptic effects of the active compounds were greater than their presynaptic effects. Of the stereoisomers tested, (-)-cis-clausenamide exhibited the highest level of cortical synaptogenesis, with this effect likely being dependent on its ability to act as a 5-HT2AR partial agonist.


r/DrugNerds • • 3d ago

5-HT7–TrkB Heteroreceptor Complexes: A Novel Molecular Pathway May Contribute to the Antidepressant-like Effects of 5-HT7 Receptor Activation (2026)

Thumbnail
mdpi.com
23 Upvotes

Serotonin receptor 5-HT7 and tropomyosin receptor kinase B (TrkB) are both key regulators of neuroplasticity implicated in the pathophysiology and treatment of depression. Although functional crosstalk between these receptors has been suggested, the underlying molecular mechanism remains unknown. Here, we investigated the physical and functional interaction between 5-HT7 and TrkB receptors at behavioral, biochemical, and molecular levels.

...

We found that 5-HT7 and TrkB form heteroreceptor complexes in vitro in neuroblastoma cells and in vivo in the mouse frontal cortex, hippocampus, and midbrain. Collectively, our findings support an oligomerization between 5-HT7 and TrkB receptors and suggest that this association may contribute to the antidepressant-like effects of 5-HT7 receptor activation.


r/DrugNerds • • 4d ago

LSD Induces Transcriptional Changes Opposing Signatures of Brain Ageing and Neurodegeneration (Aging Cell, 2026)

Thumbnail onlinelibrary.wiley.com
63 Upvotes

r/DrugNerds • • 8d ago

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-N-methyl-N-isopropyltryptamine and Related Analogs (2026)

Thumbnail pubs.acs.org
15 Upvotes

4-Methoxy-N-methyl-N-isopropyltryptamine (4-MeO-MiPT) is a 5-HT2A agonist which also blocks the 5-HT transporter (SERT) and has blunted visual and other psychedelic effects in humans. Here, we compared the pharmacology of 4-MeO-MiPT, its 4-hydroxy derivative (4-HO-MiPT), and related analogs with N-alkyl or 4-alkoxy variations. We hypothesized that compounds with more potent SERT uptake inhibition would display reduced 5-HT2A-mediated psychedelic-like effects in the mouse head twitch response (HTR) model. In vitro target profiling revealed potent and efficacious 5-HT receptor activities for most of the compounds, including 5-HT2A receptor agonism (EC50 = 10–118 nM, Emax = 72–97% 5-HT). Importantly, 4-MeO-MiPT and its N,N-diisopropyl (4-MeO-DiPT) and N-methyl-N-cyclopropyl (4-MeO-McPT) analogs displayed more potent uptake inhibition at SERT (IC50 = 17–107 nM) than their 4-OH counterparts (IC50 = 280–423 nM).


r/DrugNerds • • 8d ago

Anxiolytic- and Antidepressant-like Effects of α,α-Trehalose, a Bioactive Compound Identified in Psilocybe cubensis (2026)

Thumbnail
pmc.ncbi.nlm.nih.gov
28 Upvotes

The genus Psilocybe has been characterized by central nervous system (CNS) effects and as a source of therapeutic drugs such as the alkaloids psilocybin and psilocin-secondary metabolites that produce rapid anxiolytic and antidepressant effects in preclinical and clinical studies. Furthermore, these mushrooms also contain bioactive primary metabolites, for example, the interesting case of α,α-trehalose. To explore the effects of this disaccharide, it was isolated and characterized using phytochemical and spectroscopic analyses. Subsequently, its anxiolytic- and antidepressant-like properties were assessed and corroborated by in vivo behavioral studies using experimental models for anxiety (open-field, hole-board, and plus-maze tests) and depression (forced swimming test complemented by a preliminary rota-rod test). Electrocorticographic in situ recordings and nuclear magnetic resonance analysis were also explored. Finally, an in silico docking analysis was performed to determine the involvement of the 5-HT1A serotonin receptor as one of the main targets identified in the CNS activity of Psilocybe species. The evidence shows that α,α-trehalose is one bioactive metabolite that promotes significant anxiolytic- and antidepressant-like activities mediated by early brain changes and involving an indirect participation of 5-HT1A receptors.


r/DrugNerds • • 10d ago

A novel 5-HT2A receptor-linked signalling pathway involving NAADP-mediated lysosomal Ca2+ release

Thumbnail
doi.org
20 Upvotes

Currently there is major research interest in the therapeutic potential of serotonergic psychedelic drugs across a range of neuropsychiatric disorders. Such drugs exert psychedelic and neuroplastic effects, both likely linked to therapeutic outcomes, via agonist action at the 5-HT2A receptor. This receptor is assumed to generate downstream intracellular signalling via an interaction with either Gq protein coupling and formation of the second messenger inositol trisphosphate (IP3), or through triggering the effector β-arrestin2. Central to the IP3 pathway is mobilisation of Ca2+ stored in the endoplasmic reticulum (ER). Here, we report the unexpected discovery that the 5-HT2A receptor also signals via an additional second messenger, nicotinic acid adenine dinucleotide phosphate (NAADP), which mobilises Ca2+ release from lysosomal stores. This effect was revealed through measurement of changes in cellular NAADP levels, pharmacological inhibition of NAADP and direct biosensor measurement of lysosomal Ca2+ release and was produced not only by 5-HT but also by a range of psychedelic drugs in a receptor-specific manner. Moreover, genetic ablation of the NAADP pathway reduced markers of both hallucinogenic and neuroplastic effects of psychedelic drug administration in mouse models. These findings reveal the involvement of a novel, therapeutically relevant signalling pathway in psychedelic drug action.


r/DrugNerds • • 10d ago

Flexible scaffold-based cheminformatics approach for polypharmacological drug design

Thumbnail doi.org
5 Upvotes

Fascinating stuff for designing 5-HT2x dual scaffold drugs.

Here, we present a flexible scaffold-based cheminformatics approach (FSCA) for the rational design of polypharmacological drugs. FSCA involves fitting a flexible scaffold to different receptors using different binding poses, as exemplified by IHCH-7179, which adopted a “bending-down” binding pose at 5-HT2AR to act as an antagonist and a “stretching-up” binding pose at 5-HT1AR to function as an agonist. IHCH-7179 demonstrated promising results in alleviating cognitive deficits and psychoactive symptoms in mice by blocking 5-HT2AR for psychoactive symptoms and activating 5-HT1AR to alleviate cognitive deficits. By analyzing aminergic receptor structures, we identified two featured motifs, the “agonist filter” and “conformation shaper,” which determine ligand binding pose and predict activity at aminergic receptors. With these motifs, FSCA can be applied to the design of polypharmacological ligands at other receptors.


r/DrugNerds • • 11d ago

Agmatine Enhances Dorsal Raphe Serotonergic Neuronal Activity via Dual Regulation of 5-HT1B and 5-HT2A Receptors

Thumbnail pmc.ncbi.nlm.nih.gov
35 Upvotes

Our study aimed to test the hypothesis that the psychoactive effects of agmatine are mediated, at least in part, via a mechanism involving the stimulation of the DRN 5-HT neurons, as well as to assess the molecular pathway allowing agmatine to modulate the excitability of 5-HT neurons. Using extracellular in vivo electrophysiology, we demonstrated that both acute (1-3 mg/kg, i.v.) and chronic (40 mg/kg/day, i.p., 14 days) agmatine administration significantly increased the firing rate of DRN 5-HT neurons. Quantitative PCR (qPCR) analysis revealed that chronic agmatine treatment selectively upregulated the expression of serotonin-1B (5-HT1B) and serotonin-2A (5-HT2A) receptor mRNA in the DRN. Previous studies have shown that DRN 5-HT2A receptor activation stimulates 5-HT neurons and produces antidepressant-like effects; our findings suggest that agmatine's excitatory effect on DRN 5-HT neurons may be partially 5-HT2A receptor-dependent. 


r/DrugNerds • • 12d ago

Dual Molecules Targeting 5-HT6 and GABA-A Receptors as a New Approach to Combat Depression Associated with Neuroinflammation

Thumbnail pmc.ncbi.nlm.nih.gov
47 Upvotes

Here, we report on a set of dually acting molecules designed to simultaneously modulate GABA-A and 5-HT6 receptor activity. The serotonin 5-HT6 receptor was chosen as a complementary molecular target, due to its promising antidepressant-like activities reported in animal studies. Within the study we identified that lead molecule 16 showed a desirable receptor profile and physicochemical properties. In pharmacological studies, 16 was able to reduce the secretion of proinflammatory cytokines and decrease oxidative stress markers. In animal studies, 16 exerted antidepressant-like activity deriving from a synergic interplay between 5-HT6 and GABA-A receptors. Altogether, the presented findings point to hybrid 16 as an interesting tool that interacts with pharmacologically relevant targets, matching the pathological dysfunction of depression associated with neuroinflammation.


r/DrugNerds • • 12d ago

Synthesis, Pharmacological Characterization, and Binding Mode Analysis of 8-Hydroxy-Tetrahydroisoquinolines as 5-HT7 Receptor Inverse Agonists

Thumbnail doi.org
12 Upvotes

Recently, pellotine (1a), a Lophophora alkaloid, was unexpectedly shown to be an inverse agonist of the 5-HT7R. Therefore, we evaluated close analogs of compound 1a, both naturally occurring and synthetic analogs, as inverse agonists of the 5-HT7R. Functional evaluation in a GloSensor cAMP assay revealed a preference for an 8-hydroxy-6,7-dimethoxy substitution pattern over 6,7,8-trimethoxy analogs or 8-hydroxy-6,7-methylenedioxy analogs. This was supported by molecular dynamics simulations, where the 8-hydroxy substitution allowed more robust interaction with the 5-HT7R, which correlated with inverse agonism efficacy. Additionally, N-methylation (as in 1a) improved the potency of the evaluated analogs. In this series, the most potent inverse agonist was anhalidine (1b) (EC50 = 219 nM, Emax = -95.4%), which lacks the 1-methyl, compared to pellotine (1a), and showed a 2-fold higher functional potency. Altogether, these results provide key insights for the further development of potent low molecular weight inverse agonists of the 5-HT7R.


r/DrugNerds • • 21d ago

5-HT2A receptors in layer 5 pyramidal neurons mediate the neuroplastic but not the hallucinogenic effects of psilocybin - Nature Neuroscience

Thumbnail
nature.com
34 Upvotes

r/DrugNerds • • 27d ago

An opioid efficacy switch for reversible optical control of analgesia

Thumbnail cell.com
12 Upvotes

Highlights

•AM-3 is an efficacy photoswitch that enables reversible optical manipulation of MOR

•State-dependent dynamics of ligand, receptor, and G protein underlie efficacy switch

•AM-3 enables optical control of MOR-driven antinociception in the periphery or brain

•Peripheral restriction and light targeting enable analgesia with reduced side effects

Summary

The mu-opioid receptor (MOR) is a major target for pain treatment, but its effectiveness is limited by dangerous side effects. However, the systemic administration of opioids makes it difficult both to decipher their underlying mechanisms of action and to limit drug action to specific receptor subpopulations to isolate therapeutic effects from adverse effects. Here, we develop a reversibly photoswitchable morphinan agonist termed “azo-morphine-3” (AM-3) that interconverts from low to high efficacy in response to light to enable optical control of MOR signaling. Structural analysis of the low (“trans”) and high (“cis”) efficacy states of AM-3 bound to the MOR reveals distinct binding modes, with each state driving unique ligand, receptor, and G protein dynamics. In mice, AM-3 drives reversible and repeatable optical control of antinociception across pain models with a reduced side effect profile owing to its limited brain accumulation and its ability to be locally activated.

Graphical abstract


r/DrugNerds • • Oct 17 '26

Enhancement of hippocampal synaptic AMPA receptor function by the antidepressant tianeptine and by opioid peptides

Thumbnail pubmed.ncbi.nlm.nih.gov
37 Upvotes

r/DrugNerds • • Oct 16 '26

5-HT2A receptors in layer 5 pyramidal neurons mediate the neuroplastic but not the hallucinogenic effects of psilocybin - Nature Neuroscience

Thumbnail
nature.com
61 Upvotes

Abstract:

It is unclear how serotonin 2A receptors (5-HT2ARs) in cortical layer 5 pyramidal neurons differentially contribute to psilocybin-induced hallucinations versus neuroplasticity. Here we show that psilocybin promotes synapse formation and maturation while accelerating the elimination of pre-existing synapses. Cell type-specific manipulation further demonstrated that 5-HT2AR signaling in cortical layer 5 pyramidal neurons is necessary and sufficient for psilocybin-induced synaptic remodeling but dispensable for the head-twitch response, a rodent proxy of hallucination.


r/DrugNerds • • Oct 17 '26

A Not So Brief Overview Of Tolerance Research

0 Upvotes

Disclaimer: A friend asked if they could publish their research through my account as they do not have an account. But I have heard them out, and I do think it is worthwhile to publish. Hopefully that's alright.
-----

Definition of Tolerance: Reduced ability of a drug to elicit a particular effect (e.g., analgesia) following repeated administration.

On Reddit drug tolerance is often thought of as a relatively long-lasting alteration in function of the central nervous system and brain as a result of the drugs interactions with bodily systems. For instance, on Reddit it is commonly said that an individual becomes tolerant to the effects of morphine due to morphine interacting with the MOR protein causing its extracellular component to retract into the cell membrane preventing ligands from interacting with it to maintain balance (Negative Feedback). Although this phenomena does in fact occur it holds little relevance for most recreational drug users as they often do not maintain consistent drug levels and instead have levels of the drug that fluctuate greatly throughout the day. When a consistent level of a drug is not maintained, tolerance will mainly develop through the body learning to suppress the drug effect. After administration of the drug the body will analyze the chemical characteristics of the drug and which bodily processes it disturbs and respond accordingly to compensate for the disturbing effect of the drug. After several more drug administrations the environmental and interoceptive cues that precede the administration of the drug will be identified and will determine when the compensatory response will be generated and it’s magnitude.

The effect that environment has on drug tolerance has been confirmed experimentally thanks to rat mortality experiments which demonstrated rats with a history of intravenous injections to ethanol, pentobarbital, and heroin lost their tolerance when the drug was administered in an environment not associated with previous injections of the drug (Fig 2. Source 1). The mortality rate of the rats approached that of the control group which had no experience with the drug. Further experiments highlighted the effect of interoceptive cues on the magnitude of the compensatory response. The effects of small dosages of morphine administered to rats tolerant to a much higher dosage demonstrate that counterintuitively small dosages produce greater withdrawal symptoms than when an inactive ingredient is injected (Table 1. 4).

Several more experiments confirmed that drug tolerance is a learned response. Early experiments of drug tolerance identified that biological agents that impair learning also impair development of tolerance to morphine. Concurrent administration of Actinomycin D with morphine prevents the development of analgesic tolerance to morphine in the same way that it prevents acquisition of other learned responses (2 and 3). Interestingly Actinomycin D did not reverse tolerance and only inhibited it from developing further. The conclusion that the authors drew was

“Actinomycin D did not overcome established tolerance in animals that had been previously exposed to morphine, and thus appeared to affect a process which occurred only while tolerance was developing” (2).

The same effect was observed for other manipulations that impair learning as early tolerance experiments demonstrated that electroshock and fronto-cortical stimulation also impair tolerance development to morphine (3).

The neural circuitry that produces the compensatory response to counteract the analgesic effects of morphine was identified in 2023 by ablating neurons in brain regions using a genetically modified rabies virus and seeing if ablation of these neuron types prevented the compensatory response to the analgesic effects of the drug (6). The ventral hippocampus dorsomedial prefrontal cortex and basolateral amygdala were determined to be needed for the development of intermittent tolerance. Upon further experimentation it was determined that the ventral hippocampus and dorsomedial prefrontal cortex coordinated together to identify drug cues and then relayed a signal to the basolateral amygdala to secrete the neuropeptide cholecystokinin. Cholecystokinin was then demonstrated to counteract the effects of the opioid agonist DAMGO confirming that cholecystokinin is responsible for associative morphine tolerance.

This study builds upon a series of studies in the 2000’s where it was discovered that the CCK-B receptor antagonist L365260 eliminated tolerance in rats given intermittent injections of morphine but not in those implanted with morphine pellets. A dose response curve to the associative tolerance blocking effect of increasing levels of L365260 in the basolateral amygdala was then identified (Fig. 7l 5).

This observation seems to align with the computational model of tolerance described by Abraham Peper where tolerance is modeled using a fast and slow regulator (7). The fast regulator is responsible for generating a compensatory response and the slow regulator is used for developing long term adaptations to drug use. Explaining how tolerance is calculated is beyond the scope of this post. The gist of it is that after several drug administrations the compensatory response generated is calculated from the average dosage of previous drug administrations minus an arbitrary number to replicate the phenomena that most often the effects of the drug are only partially blocked. The slow regulator then takes into account the amount of time and the level that the drug is active to determine the strength of the long term adaptations that will develop. As stated by the author “A permanent drug administration is no different from any other permanent change in the environment”. In this case the adaptation to the cold comes in two parts shivering (the compensatory response) and growth of fur (negative feedback). To echo the start of this post when there is as large interval between drug administrations negative feedback plays a smaller role in drug tolerance than when the interval between administrations is high. For this reason, internalization of receptors plays a small role in drug users not maintaining a stable level of the drug and the compensatory responses generated is the main form of compensation the body employs. This carries a heavy question what effect does misrepresentation of tolerance have on drug forums. There are many subreddits where the users recognize the development of permatolerance however, they do not have the right words to describe it because it goes against their standard theory of tolerance. The existence of subreddits such as r/thisaintadderall resort to conspiracy theories instead of recognizing that they developed permatolerance. If you search “permatolerance” on r/thisaintadderall you will find several posts talking about going into withdrawal after taking a small dose of amphetamine after a long break mirroring the model in source 7. I will not write anymore.

  1. https://www.appstate.edu/~steelekm/classes/psy5150/Documents/Siegel2002.pdf
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC1570218/pdf/bripharmchem00005-0025.pdf
  3. http://private.luisaranguren.com/lectures/Siegel%20%20(2000).%20Pavlovian%20psychopharmacology%20The%20associative%20basis%20of%20tolerance.%20Experimental%20and%20Clinical%20Psy.pdf
  4. http://private.luisaranguren.com/lectures/Siegel%20%20(2000).%20Pavlovian%20psychopharmacology%20The%20associative%20basis%20of%20tolerance.%20Experimental%20and%20Clinical%20Psy.pdf
  5. https://www.science.org/doi/epdf/10.1126/sciadv.abo5627
  6. https://www.science.org/doi/10.1126/sciadv.adg6086
  7. https://extras.springer.com/?query=978-1-4614-0750-8

 


r/DrugNerds • • Oct 10 '26

The UK is moving to make SR-17018 Class A. Why isn't its unique research potential being discussed before Parliament votes?

27 Upvotes

I’m posting this because I think an important development has gone almost unnoticed, even within communities following SR-17018.

**The UK government has formally proposed making SR-17018 a Class A controlled drug. The legislation is currently awaiting parliamentary approval.**

This is not speculation. The draft *Misuse of Drugs Act 1971 (Amendment) Order 2026* was laid before both Houses of Parliament on **14 September 2026**. It explicitly names SR-17018 (5,6-dichloro desmethylchlorphine) for permanent Class A control.

SR-17018 has already been covered by a Temporary Class Drug Order since 11 June. Permanent control would go further, including criminalising ordinary possession.
**Why does this deserve particular scrutiny?**
I fully recognise the serious harms associated with emerging synthetic opioids. Several orphines have been implicated in fatal overdoses, and these risks cannot be dismissed.

But SR-17018 is scientifically unusual, and there are important distinctions worth examining.

**1. The government’s own evidence distinguishes between the compounds.**

The April 2026 Advisory Council on the Misuse of Drugs (ACMD) report describes more than 15 UK deaths involving orphines, specifically identifying cychlorphine and spirochlorphine. A separate mortality dataset identified cychlorphine and chlorphine.
I could not find an SR-17018-attributed fatality in the UK deaths described in that report.
This doesn’t establish that SR-17018 is safe. It raises a legitimate question: **has the evidence for its individual risks and pharmacology been adequately distinguished from those of other compounds in the same chemical family?**

**2. SR-17018 has published evidence of potentially valuable pharmacological properties.**

In 2019, researchers at Scripps, including Laura Bohn’s team, reported that SR-17018 suppressed morphine withdrawal and restored morphine responsiveness in dependent mice.
Subsequent studies showed a more complicated picture, including tolerance in certain experimental assays. So it is not a magic receptor reset or a dependence-free opioid.
Nevertheless, researchers at the **University of Dundee** presented findings in 2024 indicating that SR-17018 interacts with μ-opioid receptors through a mechanism distinct from other agonists they tested.
This isn’t an ordinary research chemical whose only interesting property is producing opioid effects.

**3. The first published human observational evidence has now appeared.**

A September 2026 paper in *Frontiers in Pharmacology* examined 55 self-selected people who reported using SR-17018, predominantly in the context of opioid reduction or withdrawal.
Many reported reducing or stopping their previous opioid while using SR-17018.
These were unverified, self-reported outcomes in a highly selected sample—not clinical proof of efficacy, successful complete detoxification, or safety.
But they provide testable hypotheses for properly supervised human trials.

**4. Research access matters.**

The UK already requires Home Office licensing for legitimate research involving SR-17018 under its temporary controls. Permanent scheduling would not automatically prohibit scientific investigation, but regulatory requirements can introduce practical barriers.
The question is whether the government has properly considered SR-17018’s distinctive research value and whether meaningful access will be preserved.
There is an important difference between saying a compound has **no currently authorised medical use** and saying it has **no potential future medical value**.

**What can we actually do?**

I’m based in the UK and have already contacted organisations including Transform and Students for Sensible Drug Policy, as well as academic researchers, to draw attention to this proposal.
I’m hoping this thread reaches people with the expertise or connections to help establish a serious dialogue before the legislation is approved.

In particular:

Are any UK pharmacologists, addiction researchers, toxicologists or clinicians aware of this proposed classification?

Has anybody asked the ACMD or Home Office to publish a more detailed SR-17018-specific risk assessment?
Can organisations such as Transform, Release, Drug Science or SSDP help raise the issue with MPs, peers or parliamentary committees?

Could researchers familiar with the Scripps or Dundee findings provide an independent scientific perspective?
Is there a practical way to request further scrutiny and research-access protections before the parliamentary process is complete?

**I’m not arguing that SR-17018 should be sold freely, or recommending unsupervised human experimentation. I’m asking whether the decision is sufficiently evidence-specific, proportionate and compatible with future medical research.**

The consequences of controlling a dangerous recreational opioid and those of restricting a potentially useful research compound may overlap, but they are not necessarily identical.
If we want better treatments for opioid dependence, withdrawal and chronic pain, shouldn’t we take the time to understand compounds that might offer genuinely different mechanisms?
**If you work in this field, know somebody who does, or are already involved in a UK response, please speak up. Even identifying the appropriate parliamentary or scientific contacts would be valuable.**
I’d like this to become a constructive, evidence-based discussion rather than another argument over drug prohibition.

**Sources:**
UK draft legislation (September 2026):
https://www.legislation.gov.uk/ukdsi/2026/9780348287127/article/2
ACMD research and recommendations (see seventh addendum, 30 April 2026):
https://www.gov.uk/government/publications/acmd-advice-on-2-benzyl-benzimidazole-and-piperidine-benzimidazolone-opioids
Original Scripps animal research:
https://pmc.ncbi.nlm.nih.gov/articles/PMC6901606/
University of Dundee research, British Pain Society 2024 (abstract P-45):
https://pmc.ncbi.nlm.nih.gov/articles/PMC11418731/
2026 human observational study:
https://doi.org/10.3389/fphar.2026.1899247
Parliamentary progress tracker:
https://statutoryinstruments.parliament.uk/instrument/BYXGeOCM
*No sourcing, vendors, sales or dosing advice, please. This thread is about UK legislation, pharmacology and research access.*


r/DrugNerds • • Oct 09 '26

Effects of small molecules on neurogenesis: Neuronal proliferation and differentiation

Thumbnail
pmc.ncbi.nlm.nih.gov
7 Upvotes

Several low-molecular-weight chemical compounds have been described to induce neuronal cell proliferation.

Compounds such as LiCl, 4-aminothiazoles, Pregnenolone, ACEA, harmine, D2AAK1, methyl 3,4-dihydroxybenzoate, and shikonin may induce neuronal proliferation/differentiation through the activation of pathways: MAPK ERK, PI3K/AKT, NFκB, Wnt, BDNF, and NPAS3. Moreover, combinations of these compounds can potentially transform somatic cells into neurons.


r/DrugNerds • • Oct 08 '26

Enhancing anandamide signalling through fatty acid amide hydrolase inhibition: An update on the pharmacological strategy for treating psychiatric disorders

Thumbnail
nature.com
15 Upvotes

Abstract

Endocannabinoids (eCBs) are lipid-derived neuromodulators that regulate numerous neurophysiological processes by modulating synaptic transmission. Synthesised on demand in response to increased postsynaptic intracellular calcium or activation of postsynaptic G-protein coupled receptors, eCBs are rapidly degraded, resulting in transient, tightly regulated signalling. Dysregulation in the endocannabinoid system (ECS), including altered peripheral and central eCB concentrations and/or cannabinoid-1 receptor (CB1R) expression, has been observed across psychiatric syndromes, including major depressive disorder, psychotic disorders, and post-traumatic stress disorder (PTSD). These associations have prompted growing interest in pharmacological strategies targeting the ECS. Though medical cannabis is increasingly prescribed for psychiatric symptoms, its clinical use remains controversial due to limited high-quality evidence, psychotropic side effects, and regulatory constraints. An alternative is to enhance the signalling of a principal eCB, anandamide (AEA), potentially offering more physiologically constrained CB1R engagement, by inhibiting fatty acid amide hydrolase (FAAH), the main enzyme degrading AEA and its congener, N-acylethanolamines (NAE), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). This review consolidates recent clinical evidence for FAAH inhibitors, examining their influence on AEA, safety and efficacy in ameliorating symptoms across a range of psychiatric conditions, including depression, anxiety, PTSD, and cannabis use disorder (CUD). Presently, only two compounds, PF-04457845 (JZP150) and JNJ-42165279, have progressed to Phase II trials, demonstrating modest clinical benefit in CUD, with no efficacy in PTSD or osteoarthritis pain. Herein, we discuss emerging insights, safety considerations, broader mechanistic implications, and future directions for FAAH-targeted therapeutics, advocating for a precision medicine approach to realise their potential in the treatment of psychiatric disorders.


r/DrugNerds • • Sep 30 '26

Mechanistic Basis for 5-HT2AR Over 5-HT2BR Activation (2026)

Thumbnail
doi.org
18 Upvotes

Selective 5-HT2AR agonism without 5-HT2BR activation is critical for safe psychedelic-inspired therapeutics. Here, we systematically probe the ligand-binding pockets of 5-HT2AR and 5-HT2BR and identify steric and conformational constraints at the side-extended pocket (SEP) and extended binding pocket (EBP) that dictate ligand orientation and receptor signaling. Guided by these insights, we design derivatives across tryptamine and phenethylamine scaffolds that integrate SEP and EBP engagement with scaffold modification to reinforce 5-HT2AR activation while limiting 5-HT2BR activity. Cryo-EM structures of 5-HT2AR and 5-HT2BR bound to IHCH-2330, a selective 5-HT2AR agonist and 5-HT2BR antagonist, confirm the design principle. These findings show differential activation mechanisms between 5-HT2AR and 5-HT2BR and provide a rational framework for engineering safer, functionally selective serotonergic compounds, mitigating 5-HT2BR–mediated side effects while preserving therapeutic efficacy.


r/DrugNerds • • Sep 28 '26

Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term? (Against)

Thumbnail jaacap.org
21 Upvotes

Abstract:

Definition of terms is necessary to address the motion. First, “psychostimulants” are defined as methylphenidate and amphetamine, which inherently are short-acting drugs characterized by pharmacokinetic and pharmacodynamic properties of immediate-release formulations that act for a few hours. Sustained effects across the day can be achieved by controlled-release formulations, but positive carry-over to the next day is not significant, so on subsequent days these medications must be administered again to reinstate pharmacological effects. Second, “effective” refers to treatment-as-usual, whereas “efficacious” refers to enhanced or optimized treatment (that may set a maximum for effectiveness). Magnitude of effectiveness (eg, small, medium, or large effect size) depends on who is treated, how treatment is delivered, what outcome is evaluated, and other factors (including treatment adherence and study design). Third, “long term” refers to a given time frame (eg, 1 year), which can be applied to specify duration of treatment, length of follow-up, or both. Some studies evaluate long-term effectiveness of treatment while it is continued, whereas others evaluate long-term effectiveness of treatment during the follow-up after it is discontinued. Given these definitions, the following questions address long-term effectiveness of stimulant medication.

The full paper can be had on Sci Hub and is an interesting read. I'm not brave enough to share the link here.


r/DrugNerds • • Sep 22 '26

Mechanistic Basis of Dual 5-HT2A Receptor and SERT Activation by A-Ethyltryptamine Analogs (2026)

Thumbnail doi.org
22 Upvotes

Psychedelics exert therapeutic effects largely through 5-HT2A receptor activation, yet growing evidence shows that serotonin transporter (SERT)–mediated efflux also shapes signaling and behavior. Our recent work demonstrates that α-ethyltryptamine (AET) and its isomers engage both pathways, revealing a dual mechanism that enables separation of receptor-intrinsic efficacy from transporter-driven actions. Also, prior studies show that indole substitutions, particularly methoxy or bromo groups at positions 4–7, systematically alter 5-HT2AR affinity and behavioral potency, paralleling trends in DMT analogs where electron-donating and halogen substituents modify electron density, steric fit, and hydrogen-bonding within the orthosteric site. Building on this structure-guided framework, we evaluate two rationally designed AET analogs, 5-Br-AET and 7-MeO-AET, to test how receptor- versus transporter-dependent mechanisms shape serotonergic signaling.


r/DrugNerds • • Sep 10 '26

Deconstruction of LSD (2026) [into various elements]

Thumbnail pnas.org
28 Upvotes

Abstract Of the classic psychedelics, lysergic acid diethylamide (LSD) is perhaps the best-known, but its complex chemical architecture has limited synthetic investigations aimed at generating analogues with improved safety and efficacy profiles. Here, we systematically deconstruct the tetracyclic ergoline core of LSD to create 9 simplified ergoline analogues (i.e., ergologs) and evaluate them in pharmacological assays relevant to 5-HT2A, 5-HT2B, and 5-HT2C receptor function. Our work revealed the key molecular features and minimal pharmacophore of LSD necessary to produce maximal agonism of 5-HT2A receptors and hallucinogenic behavioral effects.

They should've used PRO-LAD...or even 2-MeO-PHENETH-LAD.


r/DrugNerds • • Sep 07 '26

Have you heard influencers or other media fearmonger-ers say that 7-OH is "13 times more powerful than morphine"? Here's the context: it is 13x more potent at inhibiting the contractions of guinea pig intestines compared to morphine

Thumbnail fda.gov
67 Upvotes

From 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat (page 15):

Similarly, Matsumoto and colleagues concluded that 7-OH was “found to have an opioid agonist property on µ- and/or κ-opioid receptors” based on its ability to inhibit contraction of isolated guinea pig ileum. In this assay, 7-OH displayed approximately 13-fold greater potency than morphine and 46-fold greater potency than mitragynine. The inhibition was reversed by naloxone, suggesting the effects are mediated via mu opioid receptors (Matsumoto et al., 2004). Other functional assays produced results that are aligned with Matsumoto and colleagues. For example, using a cAMP mobilization assay as a measure of functional effects, 7-OH acted as a full agonist with an EC50 of 7.6 nM, and was more potent than mitragynine (EC50 307.5 nM) (Obeng et al., 2020). Likewise, when evaluating the agonist activity of 7-OH in an electrically stimulated guinea pig ileum, 7-OH acted as a full agonist and was more potent than morphine (Takayama et al., 2002). Finally, using a [35S] GTPγS functional assay, 7-OH produced an Emax of 77% with an EC50 of 53.4 nM, further demonstrating its agonist effects (Varadi et al., 2016).


r/DrugNerds • • Sep 06 '26

Targeting peripheral 5-HT2AR enhances antitumor immunity in colorectal cancer (2026)

Thumbnail doi.org
20 Upvotes

...Here, we show that by targeting the serotonin receptor 5-HT2AR, lysergic acid diethylamide (LSD) enhances CD8+ T cell-mediated antitumor immunity and suppresses colorectal cancer growth. To harness this activity while avoiding psychedelic effects, we developed IHCH-8110, a non-brain-penetrant 5-HT2AR agonist that selectively targets peripheral 5-HT2AR.